JP2019513009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513009A5 JP2019513009A5 JP2018545230A JP2018545230A JP2019513009A5 JP 2019513009 A5 JP2019513009 A5 JP 2019513009A5 JP 2018545230 A JP2018545230 A JP 2018545230A JP 2018545230 A JP2018545230 A JP 2018545230A JP 2019513009 A5 JP2019513009 A5 JP 2019513009A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- immune cell
- modified immune
- cdr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022088103A JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020057.2 | 2016-02-25 | ||
| EP16020057 | 2016-02-25 | ||
| PCT/US2017/019301 WO2017147383A1 (en) | 2016-02-25 | 2017-02-24 | Modified cells for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088103A Division JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513009A JP2019513009A (ja) | 2019-05-23 |
| JP2019513009A5 true JP2019513009A5 (https=) | 2020-04-02 |
| JP7082574B2 JP7082574B2 (ja) | 2022-06-08 |
Family
ID=55446573
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545230A Expired - Fee Related JP7082574B2 (ja) | 2016-02-25 | 2017-02-24 | 免疫療法用改変細胞 |
| JP2018544554A Expired - Fee Related JP7080819B2 (ja) | 2016-02-25 | 2017-02-24 | Ｐｄ－ｌ１に対する結合メンバー |
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544554A Expired - Fee Related JP7080819B2 (ja) | 2016-02-25 | 2017-02-24 | Ｐｄ－ｌ１に対する結合メンバー |
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20190048085A1 (https=) |
| EP (3) | EP3420000A1 (https=) |
| JP (3) | JP7082574B2 (https=) |
| KR (2) | KR20180111870A (https=) |
| CN (3) | CN116082505A (https=) |
| AU (2) | AU2017223846A1 (https=) |
| BR (2) | BR112018067698A2 (https=) |
| CA (2) | CA3014067A1 (https=) |
| ES (1) | ES2903408T3 (https=) |
| RU (2) | RU2018128464A (https=) |
| SG (2) | SG11201807188VA (https=) |
| WO (2) | WO2017147383A1 (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| US20190048085A1 (en) | 2016-02-25 | 2019-02-14 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
| TWI910495B (zh) | 2016-05-13 | 2026-01-01 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| GB201617714D0 (en) * | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
| KR20240007775A (ko) | 2016-12-08 | 2024-01-16 | 이매틱스 바이오테크놀로지스 게엠베하 | T 세포 수용체 및 이를 사용하는 면역 요법 |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| JP7275043B2 (ja) | 2016-12-16 | 2023-05-17 | ビー－モーゲン・バイオテクノロジーズ，インコーポレーテッド | 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法 |
| MA47604A (fr) | 2017-02-21 | 2020-01-01 | Regeneron Pharma | Anticorps anti-pd-1 pour le traitement du cancer du poumon |
| WO2018191619A1 (en) | 2017-04-13 | 2018-10-18 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| KR20190139216A (ko) | 2017-04-28 | 2019-12-17 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법 |
| US12415844B2 (en) | 2017-12-20 | 2025-09-16 | Poseida Therapeutics, Inc. | BCMA specific VCAR compositions and methods for use |
| WO2019141774A1 (en) * | 2018-01-19 | 2019-07-25 | Miltenyi Biotec Gmbh | Regulatory t cell expressing a chimeric antigen receptor |
| CA3089230A1 (en) | 2018-03-02 | 2019-09-06 | Cdr-Life Ag | Trispecific antigen binding proteins |
| CA3095076A1 (en) * | 2018-03-29 | 2019-10-03 | Adagene Inc. | Anti-pd-l1 antibodies and use thereof |
| WO2019234580A1 (en) * | 2018-06-04 | 2019-12-12 | Diatheva S.R.L. | Anti-cd99 diabody or igg antibody and uses thereof |
| CA3104288A1 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| JP7003295B2 (ja) * | 2018-06-29 | 2022-01-20 | ワイ－バイオロジクス・インコーポレイテッド | Ｌａｇ－３に特異的に結合する単クローン抗体及びその用途 |
| AU2019301070B2 (en) | 2018-07-09 | 2025-09-11 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| SG11202103234RA (en) * | 2018-10-01 | 2021-04-29 | Adicet Bio Inc | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| AU2019359890B2 (en) | 2018-10-17 | 2024-10-24 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| CN113226335B (zh) * | 2018-12-06 | 2023-10-13 | 广东天科雅生物医药科技有限公司 | 靶向肿瘤抗原、TGF-β、和免疫检查点的组合型TCR-T细胞疗法 |
| EP3902838A4 (en) | 2018-12-26 | 2022-12-21 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
| CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| JP7641223B2 (ja) * | 2019-01-28 | 2025-03-06 | サイフォス、バイオサイエンシズ、インコーポレイテッド | Ｃａｒ細胞上の非天然ｎｋｇ２ｄ受容体に、結合した異種分子を選択的に送達する改変非天然ｎｋｇ２ｄリガンド |
| US12589132B2 (en) | 2019-02-22 | 2026-03-31 | Five Prime Therapeutics, Inc. | CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors |
| US20220145325A1 (en) * | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| AU2020248448B2 (en) * | 2019-03-26 | 2026-01-29 | The Regents Of The University Of California | Chimeric antigen receptor modified T-cells (CAR-T) for the treatment of hematological and solid tumor cancers |
| CN110402892A (zh) * | 2019-04-30 | 2019-11-05 | 梁廷波 | 选择性敲除胰腺上皮细胞程序性死亡配体1分子的自发胰腺癌小鼠模型的建立方法 |
| CN112079924B (zh) * | 2019-06-12 | 2024-02-06 | 苏州工业园区唯可达生物科技有限公司 | Pd-l1靶向结合剂及其用途 |
| JP7678768B2 (ja) * | 2019-07-02 | 2025-05-16 | テリックス ファーマシューティカルズ （イノベーションズ） ピーティーワイ リミテッド | 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体 |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| AU2020380288B2 (en) * | 2019-11-04 | 2024-02-01 | Inovio Pharmaceuticals, Inc. | Combination therapy to treat brain cancer |
| RU2733430C1 (ru) * | 2019-11-19 | 2020-10-01 | Общество с ограниченной ответственностью «Реал Таргет» | Создание конъюгатов gd2-специфичных антител и фрагментов gd2-специфичных антител с препаратами |
| CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| EP4069294A4 (en) * | 2019-12-02 | 2024-07-10 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-l1 and methods of use thereof |
| WO2021130535A2 (en) * | 2019-12-28 | 2021-07-01 | Shanghai Cell Therapy Group Company Co., Ltd. | Cell expressing immune modulatory molecules and system for expressing immune modulatory molecules |
| EP3878858A1 (en) * | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
| CN120060368A (zh) * | 2020-03-23 | 2025-05-30 | 株式会社库利金 | 包含双特异性核酸分子的溶瘤病毒的结构 |
| AU2021252514B2 (en) * | 2020-04-06 | 2025-06-26 | Lung Biotechnology Pbc | Modular synthetic receptors and methods of use |
| AU2021256473A1 (en) * | 2020-04-17 | 2022-12-22 | The Council Of The Queensland Institute Of Medical Research | Immune cells with enhanced function |
| WO2021231975A1 (en) * | 2020-05-14 | 2021-11-18 | Virtuoso Binco, Inc. | Humanized cd38 and icam1 antibodies and uses thereof |
| EP4164696A1 (en) * | 2020-06-11 | 2023-04-19 | Innovative Cellular Therapeutics Holdings, Ltd. | Cell/gene therapies targeting mage-a4 peptide |
| WO2021262499A1 (en) * | 2020-06-25 | 2021-12-30 | Promab Biotechnologies, Inc. | Pd-l1-specific antibody and anti-pd-l1-car-t cells |
| WO2022011256A1 (en) | 2020-07-10 | 2022-01-13 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| KR20230117107A (ko) * | 2020-11-04 | 2023-08-07 | 센티 바이오사이언시스, 인코포레이티드 | 단백질 페이로드 방출 |
| CN112375743A (zh) * | 2020-11-20 | 2021-02-19 | 山东省医学科学院附属医院 | 一种分泌型靶向her2抗原的嵌合抗原受体t细胞及其应用 |
| IL303149A (en) * | 2020-11-30 | 2023-07-01 | Fred Hutchinson Cancer Center | Pd-l1 binding peptides and peptide complexes and methods of use thereof |
| EP4323389A1 (en) * | 2021-04-15 | 2024-02-21 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | T-cell receptors specific for both rac1- and rac2-derived mutated epitopes |
| CN113234152B (zh) * | 2021-06-03 | 2023-05-02 | 天津科技大学 | 程序性死亡受体-配体1(pd-l1)特异性结合多肽及应用 |
| WO2023274387A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向gd2的通用型car-t细胞及其制备方法和应用 |
| US20250179196A1 (en) * | 2021-07-30 | 2025-06-05 | Janssen Biotech, Inc. | Materials and methods of making or using il-23r binding proteins |
| IL310808A (en) | 2021-08-13 | 2024-04-01 | Inovio Pharmaceuticals Inc | Combination therapy to treat brain cancer |
| WO2023072043A1 (zh) * | 2021-10-26 | 2023-05-04 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物 |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| US20250127897A1 (en) * | 2022-01-28 | 2025-04-24 | The University Of North Carolina At Chapel Hill | Natural killer t-cells and methods of using the same |
| CN118005806B (zh) * | 2024-02-08 | 2026-01-30 | 北京市眼科研究所 | 嵌合抗原受体、人多能干细胞分化的表达嵌合抗原受体的小胶质细胞及其应用 |
| CN120518751B (zh) * | 2025-07-23 | 2025-09-19 | 中国人民解放军军事科学院军事医学研究院 | 抗人4型腺病毒特异性纳米抗体lum44及在抗病毒治疗中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
| JP2006508638A (ja) | 2002-05-22 | 2006-03-16 | エスバテック・アーゲー | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| GB0328363D0 (en) | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| ATE475669T1 (de) | 2004-06-29 | 2010-08-15 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
| PT1907424E (pt) * | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| KR101523391B1 (ko) | 2006-12-27 | 2015-05-27 | 에모리 유니버시티 | 감염 및 종양 치료를 위한 조성물 및 방법 |
| BRPI0813645A2 (pt) | 2007-06-25 | 2014-12-30 | Esbatech Alcon Biomed Res Unit | Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas |
| PL2307458T3 (pl) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
| CA2728829C (en) | 2008-06-25 | 2018-01-02 | Esbatech, An Alcon Biomedical Research Unit Llc | Solubility optimization of immunobinders |
| EP3255060A1 (en) * | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) * | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| EP3326467B1 (en) | 2011-09-16 | 2020-03-11 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR20220084444A (ko) * | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| EP3467124A1 (en) * | 2012-06-06 | 2019-04-10 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| CN113684185A (zh) * | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| IL243311B (en) | 2013-06-26 | 2022-07-01 | Numab Therapeutics AG | New frameworks for antibodies |
| WO2015038538A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
| WO2015080981A1 (en) | 2013-11-27 | 2015-06-04 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| EP4166148B1 (en) * | 2014-06-06 | 2026-02-18 | Memorial Sloan-Kettering Cancer Center | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| RU2715038C2 (ru) * | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
| EP3189073B2 (en) | 2014-09-04 | 2025-06-11 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| JP2017529851A (ja) | 2014-09-26 | 2017-10-12 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター |
| EP3212774A4 (en) | 2014-10-31 | 2018-04-11 | Baylor College of Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| EP3233900A2 (en) | 2014-12-19 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptors and methods of use thereof |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| US20190048085A1 (en) * | 2016-02-25 | 2019-02-14 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
-
2017
- 2017-02-24 US US16/079,202 patent/US20190048085A1/en not_active Abandoned
- 2017-02-24 CN CN202211150762.0A patent/CN116082505A/zh active Pending
- 2017-02-24 US US16/079,210 patent/US11434294B2/en active Active
- 2017-02-24 ES ES17711573T patent/ES2903408T3/es active Active
- 2017-02-24 WO PCT/US2017/019301 patent/WO2017147383A1/en not_active Ceased
- 2017-02-24 CN CN201780012727.3A patent/CN108699153B/zh not_active Expired - Fee Related
- 2017-02-24 EP EP17710091.4A patent/EP3420000A1/en not_active Withdrawn
- 2017-02-24 EP EP17711573.0A patent/EP3420001B1/en active Active
- 2017-02-24 BR BR112018067698A patent/BR112018067698A2/pt not_active Application Discontinuation
- 2017-02-24 AU AU2017223846A patent/AU2017223846A1/en not_active Abandoned
- 2017-02-24 JP JP2018545230A patent/JP7082574B2/ja not_active Expired - Fee Related
- 2017-02-24 SG SG11201807188VA patent/SG11201807188VA/en unknown
- 2017-02-24 RU RU2018128464A patent/RU2018128464A/ru not_active Application Discontinuation
- 2017-02-24 KR KR1020187024673A patent/KR20180111870A/ko not_active Ceased
- 2017-02-24 EP EP21209739.8A patent/EP4086285A1/en not_active Withdrawn
- 2017-02-24 CA CA3014067A patent/CA3014067A1/en active Pending
- 2017-02-24 SG SG11201807187XA patent/SG11201807187XA/en unknown
- 2017-02-24 AU AU2017224843A patent/AU2017224843A1/en not_active Abandoned
- 2017-02-24 JP JP2018544554A patent/JP7080819B2/ja not_active Expired - Fee Related
- 2017-02-24 WO PCT/EP2017/054367 patent/WO2017144681A1/en not_active Ceased
- 2017-02-24 CN CN201780012682.XA patent/CN108884164B/zh not_active Expired - Fee Related
- 2017-02-24 CA CA3014001A patent/CA3014001A1/en active Pending
- 2017-02-24 RU RU2018128462A patent/RU2018128462A/ru not_active Application Discontinuation
- 2017-02-24 KR KR1020187027644A patent/KR20190003938A/ko not_active Ceased
- 2017-02-24 BR BR112018067696A patent/BR112018067696A2/pt not_active Application Discontinuation
-
2022
- 2022-05-30 JP JP2022088103A patent/JP2022116230A/ja active Pending
- 2022-08-30 US US17/823,355 patent/US20230235061A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513009A5 (https=) | ||
| JP2019525738A5 (https=) | ||
| JP2022512684A5 (https=) | ||
| JP2019532017A5 (https=) | ||
| JP2019515646A5 (https=) | ||
| JP2020530289A5 (https=) | ||
| JP2022111148A5 (https=) | ||
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| JP2018520657A5 (https=) | ||
| JP2022504802A5 (https=) | ||
| IL263542B2 (en) | Bispecific antibodies inhibit immunological checkpoint | |
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2019513370A5 (https=) | ||
| JP2019510733A5 (https=) | ||
| JP2017504578A5 (https=) | ||
| JP2020508655A5 (https=) | ||
| JP2017522893A5 (https=) | ||
| JP2019513725A5 (https=) | ||
| JP2020524000A5 (https=) | ||
| JP2018528776A5 (https=) | ||
| JP2018520993A5 (https=) | ||
| JP2023519099A5 (https=) | ||
| JP2019518721A5 (https=) | ||
| IL273402B2 (en) | Antibodies against human leukocyte antigens type A2 and methods of using them | |
| JP2016531907A5 (https=) |